Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products.

Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex ...

Gene therapy developer CRISPR Therapeutics AG (CRSP) is navigating some regulatory and commercial dynamics. Its flagship gene ...

Learn More » CRISPR Therapeutics (NASDAQ: CRSP) is a biotech that generally tackles specialties different from those of Vertex, though it has partnered with Vertex on certain programs.

Partnered with Vertex Pharmaceuticals (VRTX), CRISPR ... CRSP since Trump and Kennedy Jr. have entered the fray. Is CRISPR Therapeutics a Buy, Hold, or Sell? Questions Remain Despite Near ...

Vertex then bet heavily on its CF research and scored a win: The company now has five commercialized CF treatments, including one approved early this year. CRISPR Therapeutics (NASDAQ: CRSP ...